About This Video

In the fight against cancer, standard of care is king. It would be unethical not to use every treatment at our disposal. So what happens when an overseas researcher discovers that they can do more with less? What does it mean for pharmaceuticals when a clinical trial fails in America, but works beautifully in Japan? Oncologist Olufunmilayo Olopade and geneticist Eric Lander address the growing realization that the standard of care may have to shift, and just as the human genome is spread across the globe, so must the effort to find the cure.
More from this series: Cancer’s Last Stand

Recorded June 2011; Posted July 2011